Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the…
By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of…
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center,…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina,…
By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…